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The Editorial on the Research Topic
Glial Plasticity in Depression
Depression is a highly prevalent disorder that poses a significant social burden to society.
Despite continued advances toward the understanding of the pathophysiology of this disease,
its molecular/cellular underpinnings remain elusive, which may be at the basis of the lack of
effective treatment strategies. Among the different lines of research, recent literature suggests that
impaired neuron and glial plasticity may be a key underlying mechanism in the precipitation of
the disorder. Surprisingly, glial cells appear to be involved both in the pathophysiology of major
depression and in the action of antidepressants. In particular, several works refer to alterations
in the morphology and numbers of astrocytes, microglia, and oligodendrocytes in the context of
depression, in human patients, and animal models of depression. These observations are linked
to functional evidences, such as impairments in the cross-talk between glia and neurons, changes
in the level of neurotransmitter or immunoactive substances, myelination status, and synapse
formation, maintenance or elimination.
This Research Topic highlights the roles played by neurons, astrocytes, and microglia in
depressive disorder(s). Polyakova et al. begin by suggesting the astrocytic S100B as a novel marker
of minor depression, specifically in males, which could help to understand its pathophysiology. The
study point outs the possible relevance of glial cells in themodulation of brain neuron-glia networks
at least in some types of depression. Rial et al. explore the multiple interactions between glial
and neuronal cells at the synaptic level, which may be impaired in depressive-like conditions. The
authors address how purines may be used to restore synaptic efficacy by modulating glia-neuron
bidirectional communication, possibly reverting depressive-like behaviors. Jo et al. discuss the
importance of the glial-mediated immune modulation through cytokine signaling that may trigger
depressive episodes, and Branchi et al. highlight that by participating actively in the modulation of
the extracellular environmentmicroglia are an integral part of brain plasticity and, therefore, appear
to account directly for the precipitation of the depressive disorder. Brites and Fernandes point out
that the disruption of secreted extracellular vesicles, an alternative form of neuro-glial signaling,
may also underlie depressive behavior. Collectively the research indicates that these novel forms of
neuro-glia communication may represent a novel approach for modulation of the brain networks
and, thus, its manipulation may allow the development of autologous therapies for depression.
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In addition to the implication of glia in the pathophysiology
(and treatment) of depression, a number of studies associates
glia-related pathways to classically accepted antidepressant
mechanisms. Specifically, in this Research Topic, Di Benedetto
et al. suggest a link between fluoxetine modulation of
aquaporin four levels in astrocytes with consequences for
astrocyte morphology and re-establishment of a functional glia-
vasculature interface, which may underlie its antidepressant
effect. Interestingly, the decreased levels of astrocyte-specific
connexin 43 (Cx43) appear to be related with antidepressant
and anti-anxiolytic phenotypes as suggested by Quesseveur et
al. Moreover, the authors suggest that the inactivation of Cx43
might induce beneficial effects through an attenuation of the
stress response, “avoiding” depressive symptoms. In accordance,
Jeanson et al. explored the effect of antidepressants on the
functional status of astrocytic connexins, showing a complex
pattern of responses that links astrocytes to the mode of action
of these drugs. Exploring the use of deep brain stimulation
(DBS) as an alternative for treatment-resistant depression
patients, Etiévant et al. discuss the beneficial role of astrocytes
in the process based on the absence of a DBS-effect after
pharmacological lesion of astrocytes.
Overall, the excellent reflections and novel data sets
that make up this Research Topic provide evidence for
a role of glial cells, namely microglia and astrocytes, in
the mechanisms underlying depression and the effect of
antidepressants. Collectively, the data indicates that despite the
rapid advancement of the field there is still a long way to
go. The study of glial cells will continue to reveal novel and
more effective therapeutic mechanisms for depression and its
symptomatology.
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